D Jeffrey Keyser Net Worth

The estimated Net Worth of D Jeffrey Keyser is at least $37.2 mil dollars as of 11 June 2020. D Keyser owns over 10,000 units of Lantern Pharma stock worth over $37,200 and over the last 4 years D sold LTRN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

D Keyser LTRN stock SEC Form 4 insiders trading

D has made over 1 trades of the Lantern Pharma stock since 2020, according to the Form 4 filled with the SEC. Most recently D bought 10,000 units of LTRN stock worth $150,000 on 11 June 2020.

The largest trade D's ever made was buying 10,000 units of Lantern Pharma stock on 11 June 2020 worth over $150,000. On average, D trades about 2,000 units every 0 days since 2020. As of 11 June 2020 D still owns at least 10,000 units of Lantern Pharma stock.

You can see the complete history of D Keyser stock trades at the bottom of the page.

What's D Keyser's mailing address?

D's mailing address filed with the SEC is 1920 MCKINNEY AVENUE, 7TH FLOOR, , DALLAS, TX, 75201.

Insiders trading at Lantern Pharma

Over the last 4 years, insiders at Lantern Pharma have traded over $6,373,290 worth of Lantern Pharma stock and bought 10,000 units worth $150,000 . The most active insiders traders include Aaron G.L.Bios Fund I, Lpbi..., Leslie W.Cavu Management, L..., eMaria Luisa Maccecchini. On average, Lantern Pharma executives and independent directors trade stock every 111 days with the average trade being worth of $423,325. The most recent stock trade was executed by Leslie W.Cavu Management, L... on 23 May 2024, trading 30,000 units of LTRN stock currently worth $189,000.

What does Lantern Pharma do?

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Complete history of D Keyser stock trades at Lantern Pharma

Lantern Pharma executives and stock owners

Lantern Pharma executives and other stock owners filed with the SEC include:

• Panna Sharma,
  Pres, CEO & Director
• David R. Margrave,
  CFO & Sec.
• Dr. Kishor Gopaldas Bhatia Ph.D.,
  Chief Scientific Officer & Scientific Consultant
• Nicole Leber,
  Fin. & Admin. Coordinator
• Dr. Peter L. Nara D.V.M., M.S., Ph.D.,
  Co-Founder & Advisor
• Park & Golf Ventures Ii, Ll...,
  
• Leslie W.Bios Equity Partne...,
  
• David S. Silberstein,
  Director
• Leslie W.Bp Directors, Lp B...,
  
• Aaron G.L.Bios Fund I, Lpbi...,
  
• Park & Golf Ventures Ii, Ll...,
  
• Arunkumar Asaithambi,
  
• Kishor G. Bhatia,
  Chief Scientific Officer
• Franklyn G Prendergast,
  Director
• D Jeffrey Keyser,
  Director
• Leslie W.Cavu Management, L...,
  
• David R. Margrave,
  Chief Financial Officer
• Panna Sharma,
  President and CEO
• Maria Luisa Maccecchini,
  Director